Vicarious Surgical (RBOT) Long-Term Deferred Tax (2020 - 2021)

Vicarious Surgical (RBOT) reported Long-Term Deferred Tax of $22.8 million for Q4 2021, up 153.16% year-over-year from $9.0 million in Q4 2020, and up 153.16% on a QoQ basis from $9.0 million in Q4 2020.

Vicarious Surgical (RBOT) has 2 years of Long-Term Deferred Tax data on file, last reported at $22.8 million in Q4 2021.

  • Quarterly Long-Term Deferred Tax rose 153.16% year-over-year to $22.8 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $22.8 million (up 153.16% YoY) and the FY2021 annual result came in at $22.8 million, up 153.16% from the prior year.
  • Long-Term Deferred Tax climbed to $22.8 million in Q4 2021 per RBOT's latest filing, from $9.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $22.8 million in Q4 2021 and bottomed at $9.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Vicarious Surgical - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 22.77 Mn
Dec 31, 2020 9.00 Mn